股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 24.1%
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2023 (10)-0.2400.0000.0000.0000.0000.000
2022 (9)0.8300.2000.00024.1000.00024.100
2021 (8)-1.4400.0000.0000.0000.0000.000
2020 (7)-1.6800.0000.0000.0000.0000.000
2019 (6)-2.2500.0000.0000.0000.0000.000
2018 (5)-2.0200.0000.0000.0000.0000.000
2017 (4)-1.9400.0000.0000.0000.0000.000
2016 (3)-1.6500.0000.0000.0000.0000.000
每股盈餘-近20季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
24Q3 (20)-0.030.085.0-0.0362.588.46-0.08-60.0-33.33
24Q2 (19)-0.03-50.0-137.5-0.0827.270-0.05-150.0-138.46
24Q1 (18)-0.0288.89-140.0-0.1131.25-320.0-0.0291.67-140.0
23Q4 (17)-0.1810.0-146.15-0.1638.46-132.0-0.24-300.0-128.92
23Q3 (16)-0.20-350.0-143.48-0.260-181.25-0.06-146.15-113.64
23Q2 (15)0.0860.00.00.00-100.000.13160.0533.33
23Q1 (14)0.05-87.18141.670.05-90.0131.250.05-93.98141.67
22Q4 (13)0.39-15.22182.980.5056.25228.210.8388.64157.64
22Q3 (12)0.46475.0355.560.320300.00.441566.67145.36
22Q2 (11)0.08166.67120.510.00100.0100.0-0.0375.096.2
22Q1 (10)-0.1274.4770.0-0.1658.9765.96-0.1291.6770.0
21Q4 (9)-0.47-161.11-683.33-0.39-143.75-62.5-1.44-48.4514.29
21Q3 (8)-0.1853.8562.5-0.1665.9664.44-0.97-22.7840.12
21Q2 (7)-0.392.532.76-0.470.011.32-0.79-97.530.7
21Q1 (6)-0.40-566.6727.27-0.47-95.830.0-0.4076.1927.27
20Q4 (5)-0.0687.589.09-0.2446.6748.94-1.68-3.725.33
20Q3 (4)-0.4817.240.0-0.4515.090.0-1.62-42.110.0
20Q2 (3)-0.58-5.450.0-0.53-12.770.0-1.14-107.270.0
20Q1 (2)-0.550.00.0-0.470.00.0-0.5575.560.0
19Q4 (1)-0.550.00.0-0.470.00.0-2.250.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2024/110.09-8.15-11.610.8626.310.25N/A-
2024/100.155.15546.30.7732.90.28N/A去年係外銷許可證因素
2024/90.06-48.3371.950.6819.260.271.64去年係外銷許可證因素
2024/80.1233.0160.620.6115.640.271.67去年未取得外銷產品許可證照
2024/70.0958.27824.130.491.690.241.85去年未取得外銷產品許可證照
2024/60.06-39.31193.70.4-15.440.212.34去年同期因外銷許可證因素導致兩期差異
2024/50.0955.9-31.10.34-26.920.212.34-
2024/40.064.5-40.110.25-25.180.172.92-
2024/30.0611.29-40.710.19-18.580.192.73-
2024/20.05-31.45-50.890.13-2.020.182.91本期較去年同期減少係負壓幫浦產品-Pump出貨減少所致
2024/10.0864.34208.110.08208.110.222.28本期較去年同期增加係負壓幫浦產品出貨增加所致
2023/120.05-53.99-73.650.73-42.780.162.96較去年同期減少係負壓幫浦產品出貨減少所致
2023/110.1571.59-15.740.68-37.820.153.15-
2023/100.02-58.72-90.790.58-40.530.14.9與主要客戶洽談訂單中
2023/90.04-21.69-77.050.57-30.440.093.88與主要客戶洽談訂單中
2023/80.05371.6-69.750.53-19.150.065.92尚未取得外銷產品許可證照
2023/70.01121.57-89.860.48-3.640.152.37尚未取得外銷產品許可證照
2023/60.0-96.76-94.830.4717.120.241.23外銷產品取得國內證照前,為保守起見與國外客戶溝通,客戶同意原定之銷貨遞延至公司取證後
2023/50.1435.5140.980.4747.510.340.89-
2023/40.13.4579.960.3350.410.310.98本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2023/30.1-7.8138.070.2340.220.231.09-
2023/20.11330.03138.130.1341.870.310.81本期較去年同期增加係負壓幫浦產品出貨增加所致
2023/10.02-85.94-48.190.02-48.190.320.78-
2022/120.1847.131933.211.27205.480.460.39本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2022/110.12-26.591455.971.1168.770.440.41本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2022/100.162.86217.850.98144.010.480.38本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2022/90.163.19122.580.81133.150.410.34本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2022/80.1558.0163.410.66135.860.340.42本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2022/70.112.83203.330.5172.980.280.5本期及本年度累計較去年同期增加係負壓幫浦產品出貨增加所致
2022/60.09-11.6876.460.4166.560.240.58本期較去年同期增加,係醫療器材委託開發收入增加,本年度累計營收較去年增加係負壓幫浦產品出貨增加所致
2022/50.172.98189.670.32209.430.230.62本期較去年同期增加,係血栓負壓移除導管系統-負壓幫浦產品出貨增加,本年度累計營收較去年增加亦因該產品出貨增加所致
2022/40.06-20.62106.240.22219.090.170.81本期較去年同期增加,係腦中風血栓負壓移除導管系統-負壓幫浦出貨增加,本年度累計營收較去年增加亦因該產品出貨增加所致
2022/30.0758.99290.550.16293.310.160.55本期較去年同期增加,係腦中風血栓負壓移除導管系統-負壓幫浦出貨增加,本年度累計營收較去年增加亦因該產品出貨增加所致
2022/20.04-6.44122.980.09295.470.10.89本期較去年同期增加,係腦中風血栓負壓移除導管系統-負壓幫浦出貨增加,本年度累計營收較去年增加亦因該產品出貨增加所致
2022/10.05451.441331.430.051331.430.061.4本期較去年同期增加,係腦中風血栓負壓移除導管系統-負壓幫浦出貨增加,本年度累計營收較去年增加亦因該產品出貨增加所致
2021/120.0112.59-85.290.42130.560.071.48本期較去年同期減少,係腦中風血栓負壓移除導管系統-負壓幫浦出貨減少,本年度累計營收較去年增加亦因該產品出貨增加所致
2021/110.01-85.0-83.450.41235.030.130.77
2021/100.05-27.97104.090.4431.980.220.46本期營收及本年度累計營收較去年增加,主係110/10委託開發服務收入及腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨增加所致
2021/90.07-24.23404.520.35596.640.20.46主係110/09委託開發服務收入及腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/80.09193.292742.590.28672.110.180.51主係110/08新增委託開發服務收入及腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/70.03-34.35173.950.18462.270.110.78主係110/07腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/60.0544.97988.410.15623.430.110.64主係110/06腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/50.0323.161316.380.1523.870.080.88主係110/05腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/40.0350.3336.520.07389.910.071.07主係110/04腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/30.02-9.22232.290.04432.770.041.44主係110/03腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/20.02500.592205.740.02904.290.080.73主係110/02腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期增加所致
2021/10.0-94.33128.760.0128.760.110.55主係泡沫式人工腦膜產品出貨所致
2020/120.0626.66787.80.189.260.130.46腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨成長所致
2020/110.0584.9741.930.12-23.290.090.7-
2020/100.0378.06-25.670.08-40.260.041.41-
2020/90.01326.88-68.530.05-45.630.032.06主係109/9腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期減少所致
2020/80.0-71.73-69.060.04-23.870.023.08主係109/8腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨較去年同期減少所致
2020/70.01160.81071.00.03-10.640.023.23主係109/7腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨量較去年同期增加所致
2020/60.088.65-21.360.02-41.060.014.57-
2020/50.0-62.0468.790.02-44.830.014.25主係109/5 醫材快速原型業務出貨量較去年同期增加所致
2020/40.0114.41-77.940.01-50.470.014.75主係109/4腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨量較去年同期減少所致
2020/30.01529.880.00.010.00.017.68主係109/3醫材快速原型業務出貨量較去年同期增加所致
2020/20.0-40.410.00.00.00.016.69主係109/2醫材快速原型業務出貨量較去年同期增加所致
2020/10.0-78.010.00.00.00.0N/A主係109/1醫材快速原型業務出貨量較去年同期增加所致
2019/120.01-79.740.00.171547.70.0N/A腦中風血栓負壓移除導管系統-負壓幫浦系統產品出貨及醫材快速原型業務成長所致

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。